Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03843658Unknown

Identifying Novel Biomarkers in Early Rheumatology Patients

Role: lead

NCT03843619Unknown

Electronic and Lab Pre-screening of New Rheumatology Patients With Rheumatoid Arthritis

Role: lead

NCT01555879Completed

Real-world Clinical Efficacy of Abatacept in the T3 Data Registry

Role: lead

NCT02742337Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Role: lead

All 4 trials loaded